Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06942104 · ClinicalTrials.gov registry record · Phase 1
Imaging of Solid Tumors Using 18F-TRX
A Phase 1 study of Solid Tumor and Metastatic Malignant Solid Neoplasm, sponsored by Rahul Aggarwal.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT06942104: Recruiting Phase 1 study of Solid Tumor and Metastatic Malignant Solid Neoplasm, sponsored by Rahul Aggarwal.
NCT06942104 is a Phase 1 study of Solid Tumor and Metastatic Malignant Solid Neoplasm that is actively recruiting participants, run by Rahul Aggarwal. The registered enrollment target is 56 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06942104, a Phase 1 study of Solid Tumor and Metastatic Malignant Solid Neoplasm, is actively recruiting participants, sponsored by Rahul Aggarwal.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
Primary Outcome
The proportion of participants with any treatment-emergent adverse events will be reported by grade and frequency per the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. All participants who receive the radiotracer injection will be evaluable.
Conditions Studied
Interventions
- PROCEDURE Blood Specimen Collection
- PROCEDURE Tumor Biopsy
- PROCEDURE Positron Emission Tomography (PET)/Computerized tomography (CT)
- DRUG 18F-TRX
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What NCT06942104 shows while recruiting
NCT06942104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (75% lower).
The record links to 10 conditions, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Blood Specimen Collection is the first listed.
NCT06942104 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06942104 about?
NCT06942104 is a clinical study titled "Imaging of Solid Tumors Using 18F-TRX". This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors...
What is the current status of trial NCT06942104?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2025-07-03. Estimated completion is 2026-09-30.
What conditions does trial NCT06942104 study?
This clinical trial studies the following conditions: Solid Tumor, Metastatic Malignant Solid Neoplasm, Stage IVB Prostate Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IV Renal Cell Cancer AJCC v8.
What interventions are being tested in trial NCT06942104?
The interventions under investigation include: Blood Specimen Collection (PROCEDURE), Tumor Biopsy (PROCEDURE), Positron Emission Tomography (PET)/Computerized tomography (CT) (PROCEDURE), 18F-TRX (DRUG).
Who is sponsoring clinical trial NCT06942104?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06942104 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06942104's enrollment target sits among peer trials
56 114th of 196 higher than 83 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI